Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Amgen, Anheart, Aslan, Astrazeneca, Blue Lake, Cstone, Cyanvac, Ena Respiratory, Genfleet, Hanmi, Harbour Biomed, Hua Medicine, I-Mab, Innovent Biologics, JW, Kyowa Kirin, Laurent, Merck, Nrx, Pfizer, Pulmotect, RDIF, Regeneron, Ribomic, Ridgeback, Roche, Senhwa, Todos Medical, Trevena, VBI Vaccines.

Sumitomo Dainippon Pharma Co. Ltd., its U.S.-based subsidiary Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Co. Ltd. have inked a global collaboration agreement to jointly advance four new compounds for serious neuropsychiatric conditions. Sunovion granted Otsuka rights to collaboratively develop and commercialize the four compounds worldwide. In return, Sunovion will receive an up-front payment of $270 million and up to $620 million in development milestone payments for the agents, with the potential for more depending on additional indications. It could also receive sales milestones from Otsuka.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aipharma Global Holdings, Anpac Bio-Medical Science, Appili, Atara, Beximco, Biocytogen, Biovaxys Technology, Cynata, Diaprost, Envigo RMS, Eyegene, Fujifilm, Genelux, GL Capital, GL Mountrose Investment Two, Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine, Hutchmed, Immutep, JCR, Jiangsu Recbio Technology, Moderna, Newsoara, Otsuka, Pierre Fabre, Race Oncology, Radiopharm Theranostics, Sanofi, Sanofi Bangladesh, Shenzhen Rhegen, Shionogi, Signalchem Lifesciences, Sihuan, Soligenix, Sumitomo Dainippon, Sunovion, Takeda, Therapeutic Solutions International, Tonix, Trilink, VBI Vaccines, Viiv Healthcare, Wuhan Rhecogen, Xuanzhu.

New hires and promotions in the biopharma industry in Asia-Pacific, including: Hangzhou Chance, Impact, Lianbio, RVAC Medicines.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Appili, Astex, Betterlife, Clover, Codagenix, Corvus, Enlivex, Gilead Sciences, Hightide, Hutchmed, Johnson & Johnson, Kyowa Kirin, Moderna, Newsoara, Otsuka, Phoxbio, Reven, Rhizen, SAB, Valneva, Zenith Epigenetics.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Advaccine, Akeso, Arcturus, Ascentage, Biogen, Biontech, Celltrion, Cytodyn, I-Mab, Innovent, Inovio, Junshi, Lion TCR, Luye, Novavax, Pfizer, Pharmamar, RDIF, Regeneron, Roche, Samsung Bioepis, Serum Life Sciences, Spero.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Abcellera, Apitope, Bio-Thera Solutions, Biovaxys, China Medical System, Cyclica, Cytodyn, D&D Pharmatech, Destiny, Eli Lilly, Elicio, Eurocine Vaccines, Geneuro, Gtreebnt, HLB Group, Immunic, Impact, Intract, Mirum, Model Medicines, Moderna, Mosaic Immunoengineering, Regenerx, SAB Biotherapeutics, Shenzhen Salubris, Takeda, Tonix, Twist, Worg.

Data to be presented at ESMO Congress 2021, including: Astellas, Astrazeneca, Carsgen, Cstone, Daiichi Sankyo, Pfizer.

New hires and promotions in the biopharma industry in Asia-Pacific, including: Brii Biosciences.